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Our project was part of a large study designed and investigated by Dr. Christopher Rose and 
Dr. Lars Marius Ytrebø. Their goal was to explore the pathophysiological mechanisms 
associated with intracranial hypertension in acute liver failure. Dr. Ytrebø`s well characterized 
large animal (porcine) model of acute liver failure was used for the study. Many different 
parameters were measured, analysed and described in this project including the beneficial 
effects of L-ornithine phenylacetate, a novel ammonia-lowering strategy. 
Our project focused on measuring the degree of brain water in different brain regions of pigs 























Background: Intracranial hypertension is a serious complication in patients with acute liver 
failure (ALF) which leads to brain herniation and 30% mortality. An increase in intracranial 
pressure (ICP) is accompanied by an increase in brain water (cerebral oedema) in which 
hyperammonemia is believed to play a major role. The aim of this study was to measure the 
amount of brain water in different regions of the brain in pigs with ALF treated with and 
without an ammonia-lowering compound, L-ornithine phenylacetate (OP).  
 
Methods: 24 Norwegian Landrace pigs were used in this study. ALF was induced by hepatic 
devascularisation (portacaval anastomosis + hepatic artery ligation) and followed by either 
treatment with OP (ALF+OP) or saline (ALF). A sham operated control group was included. 
Animal were sacrificed after 8 hours of ALF, the brain was removed and dissected into 3 
white matter and 3 grey matter regions. A sensitive gravimetric technique using gradient 
columns of specific gravity was used for measuring brain water.  
 
Results: A significant increase in brain water was found in all three grey matter regions 
(frontal and cerebellar cortex and thalamus) in pigs with ALF vs SHAM (p<0.05). ALF pigs 
treated with OP demonstrated a significant decrease in brain water in the frontal and 
cerebellar cortex vs ALF (p<0.05). A significant increase was found in frontal white matter 
and brainstem in ALF vs SHAM (p<0.05). No change was found in cerebellar white matter. 
OP-treatment resulted in a significant lowering of brain water in frontal white matter and 
brainstem vs saline-treated ALF pigs (p<0.05)  
 
Conclusion: ALF causes an increase in brain water content in 5/6 brain regions compared to 
SHAM demonstrating the brain does not swell homogeneously. OP-treatment attenuated 
ALF-induced brain water content in 4/5 regions demonstrating an association between brain 




1.1 Acute liver failure 
1.1.1 Definition 
Acute liver failure (ALF) is defined as the development of encephalopathy in the presence of 
acute liver injury of less than 8 weeks duration with no pre-existing liver failure or injury. (1) 
The major cause of death is brain herniation due to intracranial hypertension. 
 
1.1.2 Frequency and causes 
It is estimated that 5 of 6000 hospital admissions are due to ALF (1) and in the United States 
2000 people are admitted to hospital every year with this condition. The causes are numerous, 
but viral hepatitis and drug-induced liver injury are the most common, accounting for 
respectively 60-80% and 10-20%. This does not apply for all countries because of regional 
variations in both frequency and etiology. In developing nations viral hepatitis is the principal 
cause of ALF, whereas in industrialized countries paracetamol toxicity and other drug-
induced injuries are the leading cause (2). 
 
1.1.3 Clinical features   
ALF affects the physiologic status of virtually all organs in the human body and can rapidly 
progress to multiorgan dysfunction. The clinical findings that appear under the development 
of the disease all reflect a decrease in the functionality of different organs, for example 
jaundice, coagulopathy, decreased vascular resistance (hypotension), renal and electrolyte 
disturbances, hyperventilation and infections. The clinical hallmark of ALF is the 
development of hepatic encephalopathy (HE). 
 
Hepatic encephalopathy: The current definition of ALF is dependent on the development of 
HE, a neuropsychiatric syndrome that develops in patients with liver disease. The clinical 
manifestations are; personality changes, memory loss, attention deficits, decreased level of 
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consciousness, asterixis and coma. Specifically in patients with ALF, a rise in intracranial 
pressure (ICP) develops which is associated with cerebral oedema (3). 
 
 1.1.4 Prognosis 
The clinical course of ALF in a patient has one of tree outcomes: 1. Liver function recovery 
following medical treatment. 2. Liver transplantation. 3. Death. Intracranial hypertension 
secondary to cerebral oedema is the major cause of death in 50-80% of patients with ALF (4).  
 
1.2 Cerebral oedema 
1.2.1 Classification 
Different types of cerebral oedema: 
1. Cytotoxic: The oedema is caused by cell swelling as a result of changes in osmolarity.              
2. Vasogenic: The oedema is due to an increased permeability in cerebral vessels.  
3. Interstitial: The oedema is caused by increased concentrations of osmotically active solutes 
in the interstitium.     
 
1.2.2 Relationship between ICP and cerebral oedema 
The intracranial space is occupied by four entities: cerebral blood volume, cerebrospinal fluid 
(CSF), interstitial and cellular compartments. The volumes of these compartments are 
constantly being regulated to maintain a stable intracranial volume. Because the adult cranium 
is a rigid compartment there is very poor compliance and very little room to accommodate 
any increase in intracranial volume. However, due to compensatory mechanisms (ex. 
reduction in CSF) in the brain, the relationship between brain volume and intracranial 
pressure (ICP) is not linear (Fig. 1). When the increasing brain volume within the skull cannot 
be compensated for, a small increase in the intracranial volume causes a marked increase in 
ICP. In patients with ALF the rise in ICP is a result of cerebral oedema, heterogeneity of 
regional swelling within the brain and/or increase in cerebral blood flow. Because the 
relationship between brain volume and ICP is not linear, the amount of brain water/oedema 
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cannot be calculated directly from ICP, but instead has to be measured with specific methods 
(2).  
 
1.2.3 Pathophysiology of HE and cerebral oedema 
The precise etiology and pathology of HE are not known. One theory is that neurotoxic 
substances elaborated by the gut are not detoxified by the liver. The neuropsychiatric 
syndrome that develops in ALF patients is probably due to several factors acting 
synergistically however the most important factor is ammonia (5). Many studies, both in 
animals and humans, have demonstrated a close association between blood ammonia and 
increased intracranial pressure (6, 7, 8, 9). Cerebral oedema and the resulting increase in ICP 
are two major complications of ALF. The pathogenesis is not clear, but rapid accumulation of 
ammonia in the brain is regarded as one of the most important factors (Fig. 2). The increasing 
ammonia can cause astrocytic swelling via an osmotic effect with an increase in astrocytic 
glutamine concentration or by inhibition of glutamate removal from extracellular space. These 
changes could be a result of altered expression of genes in the brain, which code for proteins 
in the central nervous system, such as the glutamate transporter (GLT-1) (10).  
Cerebral oedema leading to cerebral herniation is a common cause of death in patients with 
ALF which is believed to be due to high levels of arterial ammonia (7). 
  
1.3 Therapeutic strategies at lowering ammonia 
Ammonia is regarded as one of the most important factors in the development of HE in 
patients with ALF. Therefore many treatments for HE have focused on lowering ammonia. 
There are two principal strategies for lowering of circulating ammonia: reduce ammonia 
production in the gut or increase ammonia removal capacity. Traditional treatment has tried to 
reduce the production of ammonia in the gut through the use of lactulose, which causes 
osmotic diarrhoea and reduces the time in which bacteria can metabolise proteins and produce 
ammonia. Also oral administration of non-absorptive antibiotics reduces the amount of 
ammonia producing bacteria in the gut. However, recent studies have shown that these 
strategic approaches are unsatisfactory (11, 12). One way of increasing ammonia removal is a 





Ornithine: Ammonia is normally eliminated through the urea cycle which only found in the 
liver and also by glutamine synthetase (GS), an enzyme found in the liver, brain and muscle. 
GS activity under physiological conditions in muscle is low, however during liver failure 
there is up-regulation of GS gene and protein expression along with an increase in GS activity 
(14). This means that skeletal muscle could be a therapeutic target for the treatment of 
hyperammonaemia. Increasing glutamate, a substrate for GS, would produce glutamine and 
detoxify ammonia (Fig. 3). Glutamate is provided to the muscle cell in the form of ornithine, 
which is rapidly transaminated to glutamate, because ornithine is transported into muscle cells 
whereas glutamate is not.  
 
Phenylacetate: Phenylacetate is used to lower arterial ammonia in patients with urea cycle 
enzyme deficiencies. Phenylacetate covalently combines with glutamine derived from 
glutamate to make phenylacetylglutamine, which is excreted in the urine by the kidneys. The 
binding of glutamine to phenylacetate prevents an ammonia-rebound effect since glutamine 
can be metabolised to glutamate and ammonia by phosphate-activated glutaminase (PAG) in 
the kidneys and intestine (Fig. 3). This gives the advantage that the ammonia is trapped as 
glutamine and will not return to the circulation through ammoniagenesis.  
 
Hypothesis: The administration of OP (ornithine and phenylacetate) in liver failure stimulates 
an increase in ammonia removal (ornithine) through amidation of glutamate to glutamine and 
the glutamine conjugates with phenylacetate preventing glutamine metabolism and an 










2 Aim of study 
Our aims were numerous. We first set out to determine whether brain oedema was observed 
in all 6 different brain regions measured in ALF pigs. To also see if there was a difference in 
brain water content between grey and white matter. Lastly, to see if the ammonia-lowering 



























3.1 Animal preparation 
Animals: 24 Norwegian Landrace pigs (25-30 kg) were randomised into three groups of 8 
animals each using sealed envelope system. Group 1: Sham operated (SHAM). Group 2: 
Hepatic devascularisation (portacaval anastomosis + hepatic artery ligation) (ALF). Group 3: 
Hepatic devascularisation followed by OP treatment (ALF+OP).  
 
The pigs were kept in the animal department for at least 2 days before the experiments. The 
conditions in the animal room were strictly controlled at a temperature of 21  1 C, a relative 
humidity of 55%  10%, and a 12:12-hr light/dark cycle. The pigs were premedicated with an 
intramuscular injection of ketamine (20mg/kg) and atropine (1 mg). Anaesthesia was induced 
with an intravenous bolus of 10 mg/kg pentobarbital and 10 mg/kg fentanyl and maintained 
with a central venous infusion of 4 mg/kg/hr pentobarbital, 0.02 mg/kg/hr fentanyl, and 0.3 
mg/kg/hr midazolam. The pigs were tracheostomized and intubated. Ventilation was 
maintained with an air-oxygen mixture (FiO2= .05) on a volume-controlled respirator. 
Anaesthesia was stopped after the liver was devascularised. If there were clinical signs of 
light sedation, small doses of fentanyl and midazolam were given as bolus. Sham operated 
animals received continuous anaesthesia during the experimental period and received equal 
amounts of intravenous fluids. Tidal volume was adjusted by means of repeated arterial blood 
gas analyses to achieve a PCO2 within the range of 4.5-5.0 kPa. After t = 0 hrs, no 
adjustments of ventilation were performed. Core body temperature was maintained at 38.5  
1C with a heating pad and blankets. All animals received 500 ml 0.9% NaCl containing 625 
mg of glucose as a preoperative load in order to prevent any preoperative dehydration. During 
the experiment, 0.9% NaCl was infused at a rate of 3 ml/kg/hr. 50% glucose and 20% human 
albumin (albumin 200mg/ml) were continuously infused from t = 0 hrs at rates of 0.6048 
ml/kg/hr and 0.66 ml/kg/hr, respectively.  
 
Performing an end-to-side portacaval anastomosis followed by ligation of the hepatic arteries 
induced ALF. 2500 IU heparin was given intravenously to all pigs at the start of the 
experiment. After t = 0 hrs heparin was given to keep ACT > 100 sec. The pigs were killed 
with an overdose pentobarbital and potassium chloride after t = 8 hrs. 
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3.2 OP treatment 
L-ornithine was administered intravenously at a dose of 0.05g/kg/hr and phenylbutyrate (pro-
drug for phenylacetate) was administered intraduodenally at a dose of 0.07g/kg/hr. 
Medication was administered as a continuous infusion for the duration of the experiment 
starting at T=0 and ending at T=8hrs. Physiological saline (9mg/ml) was used as vehicle in 
both the ALF and sham groups. All groups received equal amount of fluids. 
 
3.3 Brain collection 
At the end of experiment brain samples were taken from the pig for measurement of brain 
water in the tissue. 
 
With the use of a circular cranial saw the brain was removed within 5 minutes. Small cubes 
(1.5cm x 1.5cm) of brain tissue were dissected from different regions in the sacrificed brain 
and stored at 4°C until time of further dissection within 5-50 minutes. From this point we 
worked with only one cube from one specific region until brain tissue measurement was done, 
before starting with the next cube/region. Grey matter was dissected from white matter (only 
in frontal lobe and cerebellum) and dissected into very small samples (2mm x 2mm). This 
dissection was done on Petri dishes placed on ice (15). 
 
Brain water measurements were completed within 55 minutes after the small cubes of tissue 
were placed in the fridge. 
 
3.4 Gravimetric technique for measurement of cerebral oedema 
A widely used gravimetric technique using gradient columns of specific gravity was used for 
measurement of brain water. By this technique, linear and repeatable density gradients were 
prepared from which values of tissue specific gravity could be determined (15). With use of 
specific gravity of solid/dry brain tissue in pigs known from 2002 and the gravimetric 
technique, percent water per gram brain tissue was calculated (6). 
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3.4.1 Specific gravity of mixtures 
Two mixtures of kerosene (K) and bromobenzene (BB) were used in the preparation of the 
gradient. In mixture A, the proportion of the solvents was adjusted to equal a specific gravity 
(sp.gr.) of 0.9750. In the more dense solution (B), the specific gravity was adjusted to 1.0650. 
The specific gravity of BB = 1.49716 and of K = 0.78734. (15) 
 
The following procedure was used for mixing X millilitre quantities of stock A and B 
solutions. The volumes of kerosene and bromobenzene for the desired specific gravity of X 











      Eq. 1 
 
ml of K = X  – ml of BB 
 
Because of error in volume measurements, the specific gravity of the stock solutions was 
usually not equal to the desired specific gravity, and had to be corrected. To reduce the error, 
we mixed large quantities (500-2500 ml, depending on numbers of pigs per week) and never 
used stocks solutions older than one week. To adjust the specific gravity of the stock solution, 
the following rules were used: 
 
If the measured specific gravity was less than the desired value, we removed Y ml of stock 











      Eq. 2 
 
If the measured specific gravity was greater than the desired value, we removed Z ml of stock 











      Eq. 3 
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3.4.2 Preparation of gradient system 
See figure 4. At the bottom an empty 100 ml graduated cylinder is placed and filled with the 
gradient solution used to measure % of brain water in tissue. 40cm above the bottom of the 
100 ml graduated cylinder is flask B containing 100 ml of stock B (sp.gr. = 1.0650) and is 
placed on a magnetic stirrer. The magnetic stirrer must be set on low speed to avoid making 
air-bubbles. Flask A containing the lighter mixture (sp.gr. = 0.9750) was placed 43cm above 
flask B. Flask A was then connected to flask B with a polyethylene tubing (PP-60, length 
65cm, outer diameter = 1.22mm, inner diameter = 0.76mm), and flask B to the cylinder with 
two tubing, both equal to the tubing between flask A and flask B. The two tubings were 
connected side by side with a thin copper thread at each end, and with three small pieces of 
tape between, keeping the tubing connected all the way. The tape must not contact the stock 
solutions. Distances are measured from the surface of each liquid (15). 
 
We withdrew the solution into the tubing and clamped the tubing when the solution exited out 
the end. The clamping must be done carefully, not to pinch the tubing and decrease the inner 
diameter of the tubing. The tubing was not straight but curly allowing the tubing between 
flask B and the cylinder to lie against the inner wall of the cylinder. The solution therefore ran 
against the inner wall, preventing it from dripping into the column and disturbing the gradient. 
The tubing between flask A and B was taped to the top of flask B, so it dripped directly into 
the stock B solution and did not run down the inside of the flask. The last step in making the 
gradient cylinder was to release both clamps (one clamp closed both tubing from stock A to 
the cylinder, and one between stock A and B) at the same time. During the filling of the 
columns, the end of the double outflow was maintained 10mm above the surface by gradually 
lowering the cylinder 2mm at a time using a lift, as the fluid level increased. When the 
cylinder volume of 100 ml was reached the tubes were clamped at the same time, and capped 
to prevent air from reacting with the gradient. The filling process took about 20 minutes. The 
gradient was then calibrated with standards made up of potassium sulfate (K2SO4) of known 
specific gravity. (15) 
 
By this technique, the specific gravity at the bottom of the graduate cylinder is theoretically 
equal to that of stock B, while at the top of the cylinder it’s equal to the average of the specific 
gravity of the stock A and B (1.020). 
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3.4.3 Quality control 
To check for consistent flow we measured the left over volume of stock A and AB (the 
mixture between A and B contained in flask B after the cylinder reached 100 ml), and the 
specific gravity of mixture AB ( 1.020 depending on the exact specific gravity of stock A 
and B) after the cylinder is made. Together, this defines the flow rate and may explain 
deviations between the columns.  
 
We made 6 columns (cylinders) for each pig, one for each part of the brain. 
 
3.4.4 Preparation of specific gravity standards for gradient calibration 
We used reagent grade anhydrous K2SO4 to make solutions with concentrations (g/100ml) 
6.64, 5.99, 5.34, 4.70, 3.40 corresponding to specific gravities of 1.050, 1.045, 1.040, 1.035 
and 1.025. One drop of each standard was gently placed in the column using a pipette. The 
end of equilibration was recorded at the end of 1 minute. To prevent temperature difference 
interfering with the specific gravity of  K2SO4 we stored it at 4°C and took it out of the fridge 
3 hours before placing them in the column (15). 
 
3.4.5 Preparation of samples 
We studied six different parts of the brain; 3 white matter (frontal lobe white matter, 
cerebellar white matter and brainstem), and 3 grey matter (frontal cortex, cerebellar cortex 
and thalamus). Surgical instruments were used to obtain small samples (2mm x 2mm) from 
the brain. The brain was placed and dissected on a glass plate packed with ice underneath. 
The samples were carefully placed in the column with the gradient solution using a syringe 
and dissecting tweezers and the equilibration depth was recorded at the end of 2 minutes. The 
equilibration depth represents the specific gravity of the sample and the percentage of water in 
the tissue could be calculated using equation 4 below.  
 
The preparation of the liquid gradients by this technique resulted in a virtually linear 




3.4.6 Measurement of brain water 
From an earlier study we know the solid specific gravity of solid matter (sp.gr. s). These are 
constants (6). From the liquid gradient we get the specific gravity of wet tissue (sp.gr.w). With 
these two parameters known, gram water per gram tissue can be calculated by equation 4: 
(15) 
 
g H20/g tissue = 1-((sp.gr. w -1)/(1-1/sp.gr. s)sp.gr. w)    Eq. 4 
 
3.5 Source of errors 
3.5.1 Weighing errors/ solution errors. 
Weighing errors, together with dehydration of the tissue, are probably the biggest source of 
errors affecting several parts of the experiment. The scale was each day checked by measuring 
a known volume of distilled water (Sp. Gr. of distilled water = 1.00), and if differences were 
detected, a correction-number was used during all weighing.  
 
 Making of the K2SO4-solutions. 
o Inaccurate scale when weighing dry K2SO4. 
o Inaccurate pipetting or inaccurate pipette when checking the specific gravity of 
the standard solutions. 
o Temperature: To avoid this interfering with the standard curve we kept the 
solutions at 4 °C for storing and in room temperature the last 3 hours before 
use. When comparing the specific gravity of K2SO4-solutions at 4°C and 22°C 
we found no differences between 4°C and 22°C (Fig. 6 and table 1). 
 
 Making stock A and B. 
o Inaccurate scale. 
o Inaccurate measuring.1) 
 
1) 
Small differences in stock A and B will shift the gradient dramatically, so it’s extremely 
important to have the correct specific gravity of these and corrected as close as possible to the 




 Make big amounts. We made between 500 ml and 2500 ml. 
 When checking the specific gravity of the stock solutions use big volumes. We 
started with a 1 ml pipette. This is not recommended because the solutions 
have high viscosity and small volume differences will change the result 
dramatically. We ended up with using 5 ml pipette. This gave us more accurate 
measurements. 
 Shake the stock solution before every experiment. 
 
3.5.2 The stability of the gradient 
We tried to investigate how stable the gradient was over time, and we found that some 
columns were stable, while other columns changed (Fig. 7 and 8). However we could clearly 
see that columns made the same day, always behaved in the same way. They were either 
stable, or fell the same amount. To explain this we tried different theories: 
 
 Light: There is no difference between columns kept in the dark or light during the 
night. 
 Temperature: When columns kept in fridge (4C) for 15 hours the gradient shifted. 
When new K2SO4 solution was added to the column they increased with 5-18 divisions 
in the columns kept in the fridge, and the columns kept in room temperature fell 0.5-
1.5. When columns kept in water bath with 25C for 15 hours they fell 1.5-4 divisions, 
while the columns in room temperature fell 2-3. This could maybe explain some of the 
changes. 
 We compared columns with and without a cap and found no difference between them 
when checked every day for the following 3 days (Fig. 9) 
 
3.5.3 The accuracy of the gradient. 
 There are only small variations in the columns made each day. To get them as accurate 
as possible it’s important to measure the correct specific gravity of stock A and B (see 
weighing errors), and make sure the flow is stable. 
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 To increase the sensitivity of the gradient we reduced the range of the gradient. We 
made stock A with the specific gravity of 1.014 and stock B with the specific gravity 
of 1.050. 1 division in the new column would with these specific gravities be 0.4 
divisions in the old column. The coefficient of determination (R
2
) of the new columns 
was not as good as usual (about 0.9900 compared to 0.9960 in the original columns). 
In the original columns the tissue stopped after 2 minutes, but in the new columns the 
tissue kept falling at significant speed. The sensitivity of the column was measured as 
the difference between the highest and lowest tissue with the ratio 1:0.4. Fig. 10 shows 
that the new gradient was not as accurate as the original ones. 
 
3.5.4 Possible errors in flow and set up 
 The clamping of the tubes might damage the tubes. 
 The binding of the double tube with a tread might damage the tubes. 
 Dripping from the double tubing into the cylinder. 
 Tube A not dripping into flask B, but running down the inside of the flask or the 
double tubing. 
 The unclamping of the single and double tubes were not done at exactly the same 
time. 
 Displacement of flask B with the result that the magnet stopped. 
 Double tubing submerged in the solution during filling of the column. 
 High speed on the magnet might cause bubbles in the stock. 
 Tubing system not properly placed in the bottom of the flasks. 
 
3.5.5 Possible errors with the brain samples 
 Tissue samples placed into the cylinder with different force or speed. 
 Desiccating/dehydration of the samples: If dissection or immersing the samples in the 
cylinder took too long, the samples desiccated, becoming sticky and most important 
got a lower specific gravity. We put 5 samples in the cylinder first, waited for 
equilibration after 2 minutes, and put the last 3 samples in. It’s very difficult to do 
more than 5 at the time because you can easily lose track of the different tissue 
19 
 
samples. We could clearly see that the first 5 samples had higher specific gravity than 
the last 3 (Fig. 11 and 12). To decrease this source of error we kept the tissue in the 
fridge as often as possible, the dissection was done on ice, and kept the cap on the 
Petri dish as often as possible.  
 
3.5.6 Statistical analysis 
Results are expressed as meanSEM. Significance of difference between groups was tested by 
unpaired Student t test. P<0.05 was considered statistically significant. GraphPad Prism 4.0 






















4.1 Exclusions of animals 
Data from frontal cortex in pig 2 (ALF) was excluded because of abnormal results. Results 
from pig 5 (ALF+OP) was excluded because of failed OP treatment. No brain measurements 
from pig 1 (SHAM) and 6 (ALF) were done because of inaccurate gradient in columns. 
 
4.2 Cerebral oedema 
4.2.1 Grey matter 
Fig. 13 shows percent brain water in frontal cortex, cerebellar cortex and thalamus in the 3 
groups: SHAM, ALF and ALF+OP. In all three grey matters there is a significant (p<0.05) 
higher brain water content in pigs with ALF compared to SHAM. In frontal and cerebellar 
cortex there is a significant (p<0.05) lower brain water content in pigs treated with OP 
compared to pigs with ALF. There is no significant difference in percent brain water between 
ALF and ALF+OP in the thalamus.  
 
4.2.2 White matter 
Fig. 14 shows percent brain water in frontal white matter, cerebellar white matter and 
brainstem in the 3 groups: SHAM, ALF and ALF+OP. In frontal white matter and brainstem  
there is a significant (p<0.05) higher brain water content in pigs with ALF compared to 
SHAM. In frontal white matter and brainstem there are a significant (p<0.05) lower brain 
water content in pigs treated with OP compared to pigs with ALF. There is no significant 
difference in brain water content between the three groups in cerebellar white matter. 
 
4.3 ICP 
During this project co-workers measured ICP in the pigs during the experiment. They found 
that pigs with ALF had significant higher ICP compared to both SHAM and ALF+OP after 1 
hour of ALF induction, which persisted until the end of the experiment (8 hours). No 





We found that pigs with ALF had higher brain water content compared to the control group 
(SHAM) in every part of the brain except from cerebellar white matter. ALF pigs treated with 
OP had a significant lower brain water content compared to ALF pigs treated with saline in 
every part of the brain except thalamus and cerebellar white matter. 
 
The brain does not swell homogenously. Changes in brain water were different in all 6 
regions studied following 8 hours of ALF, with or without OP treatment. From our results we 
can see no clear pattern in the changes in brain water, and can’t conclude that neither grey or 
white matter have a bigger change in brain water content than the other. Why it seems like 
there is no clear pattern could be the results of either anatomical or physiological factors, or 
the fact that we only did experiments on 6 brain regions. If we had examined more white and 
grey brain regions it would be easier to detect a pattern between white and grey matter if there 
is any. 
 
In both cerebellar white matter and thalamus we can see differences in brain water content 
similar to the changes in the other parts of the brain, but these differences are not significant. 
We had few animals in each group. There is a possibility that larger number of animals could 
give us more data that would make our results more accurate, and maybe significant 
differences here too, if these tendencies are real. 
  
There is a known fact that arterial ammonia correlates with brain oedema and ICP. OP 
treatment lowers ammonia, and should therefore also lower ICP (Fig. 15). This could possibly 
explain why pigs treated with OP have lower brain water content in several regions than pigs 
with ALF. 
 
5.2 Source of errors 
During the experiment we encountered different sources of errors, both theoretical and 
practical. Our main challenge was to make a stable and accurate gradient. To examine 
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possible errors we investigated external factors that could affect both the solutions and the 
columns:  
 Temperature – No difference in specific gravity of K2SO4-solutions at 22°C vs. 4°C. 
The columns/gradients however were influenced by temperature. 
 Light – No difference between columns kept in dark and light environment. 
 Shrinking of the gradient – This made the gradient more inaccurate with lower 
coefficient of determination. The tissue kept falling at significant speed at the time of 
measurement (2 min). This time was calculated based on the original protocol. To 
reduce the gradient the time of measurement must be adjusted. The depth of 
equilibration was not reached after 2 minutes. If the time of measurement is correct 
this could be a more accurate technique. 
 
The biggest sources of errors were probably dehydration of the brain samples and inaccurate 
weighing. Accurate weighing is essential to get correct concentrations and specific gravity of 
different solutions. To reduce this error we made large amounts of solutions enough for 3 
days of experiments (18 columns). We also investigated the dehydration of the brain tissue. 
We found out that the first group of tissue samples had higher brain water content than the last 
group, probably due to dehydration. We tried to reduce this by dissecting on ice, keeping the 













ALF results in an increase in brain water content in 5/6 brain regions. This shows the brain 
does not homogeneously swell during ALF and that grey matter areas may be more 
susceptible to swelling than white matter areas. Our results also reveal cerebellar white matter 
is more resistant to oedema. OP treatment lowered brain water content in 4/5 oedematous 
brain regions induced by ALF. These results demonstrate an association between 
hyperammonemia and brain oedema in those 4 brain regions which responded to OP 
treatment. The thalamus did not respond to OP treatment and therefore its brain water content 
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Specific gravity At 22 °C At 4 °C Difference Numbers of data 
1.050 35,875 35,75 0,125 4 
1.045 47,875 47,875 0 4 
1.035 73,125 73,5 -0,375 4 
1.025 95,375 95,75 -0,375 4 
 






















































r  = 0.610
r2 = 0.372
 





























































































































Comparison of specific gravity of K2SO4-solutions at 22°C vs. 4°C. The measurements are 







































Comparison of K2SO4-solution in columns left for one day. The measurements are done in 6 






































Comparison of K2SO4–solution in columns left for between 2-6 days. The measurements are 






































Without cap day 1
Without cap day 3 or 4
With cap day 1
With cap day 3 or 4
 
 
Comparison of K2SO4–solutions in columns left for three or four days with or without a cap. 









































































The sensitivity of the columns made with a reduced gradient (Sp.Gr. 1,032-1,05) vs the 
original gradient (Sp.Gr. 1,020-1,065). Comparison of the difference between the highest and 
lowest tissue in the two columns/gradients. 1 ml in the reduced columns is equal to 0.4 ml in 
the original columns because of the reduced gradient. This ratio of 0.4 was used to calculate 




















Comparison of the average of the first group of tissue 
















Frontal cortex. Comparison of the average of the first group of tissue dropped into the column 
and the average of the second (last) group of tissue. We immersed 5 pieces the first time, 
waited 2 minutes for equilibration, then the last 3 pieces was immersed. Sometimes a piece of 





















Comparison of the average of the first group of tissue 
















Frontal white matter. Comparison of the average of the first group of tissue dropped into the 
column and the average of the second (last) group of tissue. We immersed 5 pieces the first 
time, waited 2 minutes for equilibration, then the last 3 pieces was immersed. Sometimes a 














































* = p < 0.05 vs SHAM; † = p < 0.05 vs ALF  
 












































































































ICP levels in pigs with ALF, ALF+OP, and sham operated controls (* = ALF vs sham, PGT < 
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